https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53336 Wed 28 Feb 2024 16:23:52 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:15677 Wed 11 Apr 2018 15:24:49 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:15053 Wed 11 Apr 2018 13:24:44 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25008 Tue 30 Aug 2022 14:27:23 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:575 Thu 25 Jul 2013 09:10:29 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:7113 Sat 24 Mar 2018 08:34:11 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:261 Sat 24 Mar 2018 07:42:57 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45478 65 years of age) presented with stage I-III pancreatic cancer. The majority of patients had tumors >2 cm size (82%), grade I/II (65%), lymphatic invasion (LI) (66%), and negative margins (76%). A survival advantage for adjuvant therapy was observed among all patients, independent of their risk-profile. For example, a patient =65 years of age, with early stage cancer (size =2 cm, grade I/II, -ve LI, -ve margins) who received adjuvant therapy had a 62% probability of being alive beyond three years (95%CI = 59%-66%). In contrast, the survival probability decreased to 53% (95%CI = 59%-66%) without adjuvant therapy. Conclusions: These results provide surgeons and patients with more accurate information regarding long-term survival, as well as the benefit of opting for adjuvant therapy after successful pancreatic surgery.]]> Fri 28 Oct 2022 14:36:57 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45453 Fri 28 Oct 2022 14:15:24 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41096 Fri 22 Jul 2022 18:07:18 AEST ]]>